Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound selected from the group consisting of ~~according to Formula (I)~~

- (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; and



~~the~~ pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof. ~~and the prodrugs thereof, wherein~~

~~n is 0, 1 or 2;~~

~~m is 1 or 2, provided that if m is 2, then n is 1;~~

~~p is 1 or 2;~~

~~=Q is =O or =NR3;~~

~~X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR3-;~~

~~R1 is Ar1, Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent of formula -O-CH2-CH2-O- or -O-CH2-CH2-CH2-O-;~~

~~R2 is Ar2, Ar2C1-6alkyl, Het1 or Het1C1-6alkyl;~~

~~R3 is hydrogen or C1-6alkyl;~~

~~L is hydrogen; Ar^3; C_{1-6}alkyl; C_{1-6}alkyl substituted with 1 or 2 substituents selected from hydroxy, C_{1-6}alkyloxy, Ar^3, Ar^3C_{1-6}alkyloxy and Het^2; C_{3-6}alkenyl; Ar^3C_{3-6}alkenyl; di(Ar^3)C_{3-6}alkenyl or a radical of formula~~



(a-1);



(a-2);



(a-3);



(a-4); or



(a-5);

~~wherein~~

~~each q independently is 2, 3 or 4;~~

~~each r is 0, 1, 2, 3 or 4;~~

~~each Y^1 independently is a covalent bond, -O- or NR^3;~~

~~Y^2 is a covalent bond, C_{1-4}alkanediyl or -C_{1-4}alkylNR^3-;~~

~~each -A=B independently is a bivalent radical of formula -CH=CH-, -N=CH- or -CH=N-;~~

~~each R^4 independently is hydrogen, C_{1-6}alkyl, Ar^2 or Ar^2C_{1-6}alkyl;~~

~~R^5 is hydrogen, C_{1-6}alkyl or Ar^3;~~

~~R^6 is C_{1-6}alkyl, Ar^3, Ar^3C_{1-6}alkyl, di(Ar^3)C_{1-6}alkyl, Ar^3C_{3-7}cycloalkyl, or indolyl;~~

~~R^7 is Ar^3; Ar^3C_{1-6}alkyl; di(Ar^3)C_{1-6}alkyl; C_{1-6}alkyl; C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with Ar^3; oxazolyl; oxazolyl substituted with halo~~

~~or C_{1-6}alkyl; thiazolyl; thiazolyl substituted with halo or C_{1-6}alkyl; imidazolyl; imidazolyl substituted with Ar^3, C_{1-6}alkyl, Ar^3C_{1-6}alkyl or halo; indolinyl; indolinyl substituted with C_{1-4}alkyl; 2,3,4-trihydroquinolinyl; pyrrolidinyl or furanyl;~~

~~each R^8~~ ~~independently is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl or a radical of formula of formula~~

~~-Alk-R^{11} (b-1) or~~

~~-Alk-Z-R^{12} (b-2);~~

~~wherein~~

~~Alk~~ ~~is C_{1-6}alkanediyl;~~

~~Z~~ ~~is a bivalent radical of formula -O-, -S- or -NR^3-;~~

~~R^{11}~~ ~~is phenyl; phenyl substituted with 1 or 2 substituents selected from halo, C_{1-6}alkyl or C_{1-6}alkyloxy; furanyl; furanyl substituted with 1 or 2 substituents selected from C_{1-6}alkyl or hydroxyC_{1-6}alkyl; thienyl; thienyl substituted with 1 or 2 substituents selected from halo or C_{1-6}alkyl; oxazolyl; oxazolyl substituted with 1 or 2 C_{1-6}alkyl substituents; thiazolyl; thiazolyl substituted with 1 or 2 C_{1-6}alkyl substituents; pyridinyl or pyridinyl substituted with 1 or 2 C_{1-6}alkyl substituents;~~

~~R^{12}~~ ~~is C_{1-6}alkyl or C_{1-6}alkyl substituted with hydroxy, carboxyl or C_{1-6}alkyloxycarbonyl;~~

~~Ar^1~~ ~~is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C_{1-4}alkyl, haloC_{1-4}alkyl, cyano, aminocarbonyl, C_{1-4}alkyloxy and haloC_{1-4}alkyloxy;~~

~~Ar^2~~ ~~is naphtalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halo, cyano, nitro, amino, mono- or di(C_{1-4}alkyl)amino, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-4}alkyloxy, haloC_{1-4}alkyloxy, carboxyl, C_{1-4}alkyloxycarbonyl, aminocarbonyl and mono- and di(C_{1-4}alkyl)aminocarbonyl;~~

~~Ar^3~~ ~~is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from the group consisting of halo, hydroxy, amino, nitro, aminocarbonyl, C_{1-6}alkyl, haloC_{1-6}alkyl and C_{1-6}alkyloxy;~~

~~Het^1~~ ~~is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from~~

~~the group consisting of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from the group consisting of halo, C_{1-4}alkyl or mono-, di- and tri(halo)methyl; and~~

~~Het^2 is a heterocycle selected from the group consisting of 1,4-dihydro-5-oxo-tetrazol-1-yl, imidazo[1,2-a]pyridinyl, oxazolyl and imidazolyl; each of said heterocycles may be substituted with 1 or where possible 2 substituents selected from the group consisting of C_{1-4}alkyl and Ar^3.~~

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Withdrawn) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises a compound selected from the group consisting of :

- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(1-phenylcyclohexyl)-1-piperazine acetamide;
- 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[□-(1-pyrrolidinylcarbonyl)benzyl]-1-piperazinyl]piperidine;

- 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1*H*-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; and
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide.

10. (Currently Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises ~~a compound selected from the group consisting of :~~

- ~~(+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;~~
- ~~(-)-(B)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide~~; and

(+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide (L)-malic acid (1:1).

11. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition is formulated for simultaneous, separate or sequential use.

12. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the opioid analgesic is one or more compounds selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanyl, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanyl, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl and sufentanyl; and derivatives and pharmaceutical acceptable salts thereof.

13. (Previously Amended) A pharmaceutical composition according to claim 12 wherein the opioid analgesic is one or more compounds selected from the group consisting of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and derivatives thereof.

14. (Previously Amended) A pharmaceutical composition according to claim 1 where, the pharmaceutical composition is in a form suitable to be orally administered.

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Withdrawn) A method for treating pain and/or nociception comprising administering to a person in need thereof an effective amount of a pharmaceutical composition according to claim 1.

22. (Withdrawn) A method for treating acute and chronic pain selected from the group consisting of inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.

23. (Withdrawn) A method for treating emesis in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.

24. (Withdrawn) A method for treating nausea and vomiting in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 23.

25. (Withdrawn) A method for treating respiratory depression in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an

NK_1-receptor antagonist selected from an NK_1-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.

26. (Withdrawn) A method for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK_1-receptor antagonist selected from the group consisting of an NK_1-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.